PC1 0.00% 0.0¢ plus connect limited

anyone watching

  1. 390 Posts.
    Has moved up nicely on 2M+ volume today. This biotech is undervalued compared to all the others that have run in recent weeks and 3 to 4 times price of ACU. Phase II trial completed with larger number of patients to be tested 2nd half 03. Market is finally realisng this one has been neglected. Have also heard ACU will be featured in next issue of Bulletin Investor magazine with further announcements coming out soon. Watch this space.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.